Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김완규 | * |
dc.date.accessioned | 2022-08-11T16:31:03Z | - |
dc.date.available | 2022-08-11T16:31:03Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 2287-2728 | * |
dc.identifier.issn | 2287-285X | * |
dc.identifier.other | OAK-31890 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/262302 | - |
dc.description.abstract | Background/Aims: We aimed to define an optimal target population and drug-specific biomarkers that may predict dipeptidyl peptidase (DPP)-4 inhibitor responses in non-alcoholic fatty liver disease (NAFLD). Methods: An exploration study (study I) was performed using three different NAFLD models (basket study design; high-fat diet [HFD], methionine choline-deficient diet [MCD], and high-cholesterol Western diet [WD] models). RNA transcriptome analysis was performed on pre-studied liver tissues to identify biomarkers that could predict the response to DPP-4 inhibitors. In the validation study (study II), the HFD-induced NAFLD model was divided into high and low hepatic insulin-like growth factor binding protein 1 (Igfbp-1) groups based on the pre-study liver biopsy. Results: DPP-4 inhibitor attenuated the NAFLD activity score and fibrosis stage in the HFD model but not in the WD and MCD models. The overall response rate was 19% across the modified basket NAFLD trial and 42%, 25%, and 0% in the HFD, WD, and MCD models. Hepatic Igfbp-1 expression was higher in the responder group than in the non-responder group in pre-study biopsy samples. In contrast, hepatic Igfbp-1 expression was lower in the responder group than in the non-responder group in the end-study biopsy samples. DPP-4 inhibitor response rates were 83% and 17% in the baseline hepatic high Igfbp-1 and low Igfbp-1 groups, respectively. Hepatic messenger RNA Igfbp-1 expression was positively correlated with serum IGFBP-1 levels. Conclusions: The DPP-4 inhibitor response was higher in the HFD phenotype and pre-treatment levels of hepatic or serum IGFBP-1 were high. | * |
dc.language | English | * |
dc.publisher | KOREAN ASSOC STUDY LIVER | * |
dc.subject | Biopsy | * |
dc.subject | Nonalcoholic fatty liver disease | * |
dc.subject | Dipeptidyl peptidase 4 inhibitor | * |
dc.subject | Insulin-like growth factor binding protein 1 | * |
dc.subject | Biomarker | * |
dc.title | Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial | * |
dc.type | Article | * |
dc.relation.issue | 3 | * |
dc.relation.volume | 28 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 497 | * |
dc.relation.lastpage | 509 | * |
dc.relation.journaltitle | CLINICAL AND MOLECULAR HEPATOLOGY | * |
dc.identifier.doi | 10.3350/cmh.2022.0019 | * |
dc.identifier.wosid | WOS:000827842700001 | * |
dc.identifier.scopusid | 2-s2.0-85133932393 | * |
dc.author.google | Oh, Ju Hee | * |
dc.author.google | Jun, Dae Won | * |
dc.author.google | Kim, Hye Young | * |
dc.author.google | Lee, Seung Min | * |
dc.author.google | Yoon, Eileen L. | * |
dc.author.google | Hwang, Jungwook | * |
dc.author.google | Park, Jung Hwan | * |
dc.author.google | Lee, Hanbi | * |
dc.author.google | Kim, Wankyu | * |
dc.author.google | Kim, Hyunsung | * |
dc.contributor.scopusid | 김완규(25627654100) | * |
dc.date.modifydate | 20240130091819 | * |